Skip to content

Advertisement

BMC Cancer

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study

  • Ruihua Xu1,
  • Xianjun Yu2,
  • Jihui Hao3,
  • Liwei Wang4,
  • Hongming Pan5,
  • Guohong Han6,
  • Jianming Xu7,
  • Yanqiao Zhang8,
  • Shujun Yang9,
  • Jia Chen10,
  • Jieer Ying11,
  • Guanghai Dai12,
  • Mingyu Li13,
  • Damir Begic13,
  • Brian Lu13 and
  • Lin Shen14, 15Email author
BMC Cancer201717:885

https://doi.org/10.1186/s12885-017-3887-z

Received: 19 August 2016

Accepted: 8 December 2017

Published: 22 December 2017

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting info@biomedcentral.com.

Original Submission
19 Aug 2016 Submitted Original manuscript
2 Sep 2016 Author responded Author comments - Lin Shen
Resubmission - Version 2
2 Sep 2016 Submitted Manuscript version 2
9 Jan 2017 Reviewed Reviewer Report - Arjun Kalvala
6 Feb 2017 Reviewed Reviewer Report - Linara Gabitova
28 Feb 2017 Author responded Author comments - Lin Shen
Resubmission - Version 3
28 Feb 2017 Submitted Manuscript version 3
11 Mar 2017 Reviewed Reviewer Report - Linara Gabitova
18 Mar 2017 Reviewed Reviewer Report - Roberto Passera
10 Apr 2017 Author responded Author comments - Lin Shen
Resubmission - Version 4
10 Apr 2017 Submitted Manuscript version 4
11 Apr 2017 Reviewed Reviewer Report - Roberto Passera
12 Jul 2017 Author responded Author comments - Ruihua Xu
Resubmission - Version 5
12 Jul 2017 Submitted Manuscript version 5
18 Jul 2017 Author responded Author comments - Ruihua Xu
Resubmission - Version 6
18 Jul 2017 Submitted Manuscript version 6
29 Aug 2017 Author responded Author comments - Ruihua Xu
Resubmission - Version 7
29 Aug 2017 Submitted Manuscript version 7
3 Nov 2017 Author responded Author comments - Ruihua Xu
Resubmission - Version 8
3 Nov 2017 Submitted Manuscript version 8
Publishing
8 Dec 2017 Editorially accepted
22 Dec 2017 Article published 10.1186/s12885-017-3887-z

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting info@biomedcentral.com. All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

(1)
Sun Yat-sen University Cancer Center, Guangzhou, China
(2)
Fudan University Shanghai Cancer Center, Shanghai, China
(3)
Tianjin Cancer Hospital, Tianjin, China
(4)
Renji Hospital, Shanghai Jiaotong University, Shanghai, China
(5)
Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou City, China
(6)
Xijing Hospital, Changle, China
(7)
307 Hospital of the People’s Liberation Army, Beijing, China
(8)
Harbin Medical University Cancer Hospital, Harbin, China
(9)
Henan Cancer Hospital, Zhengzhou, China
(10)
Jiangsu Provincial Tumor Hospital, Nanjing, China
(11)
Zhejiang Cancer Hospital, Hangzhou City, China
(12)
Chinese People’s Liberation Army General Hospital No.28, Beijing, China
(13)
Celgene Corporation, Summit, USA
(14)
Peking University Cancer Hospital and Institute, Beijing, China
(15)
Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China

Advertisement